相似文献
1
MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting.
J Am Chem Soc. 2010 Sep 22;132(37):12829-31. doi: 10.1021/ja105563a.
2
Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model.
Korean J Radiol. 2010 Jul-Aug;11(4):449-56. doi: 10.3348/kjr.2010.11.4.449. Epub 2010 Jun 21.
3
MRI analysis of hydrogel-loaded apatinib for local therapy of hepatocellular carcinoma model in nude mice.
Biochem Biophys Res Commun. 2019 Feb 5;509(2):529-534. doi: 10.1016/j.bbrc.2018.12.120. Epub 2018 Dec 28.
4
A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity.
J Am Chem Soc. 2008 Apr 30;130(17):5744-52. doi: 10.1021/ja711193x. Epub 2008 Apr 2.
5
The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues.
Bioorg Med Chem Lett. 2008 Nov 15;18(22):5892-4. doi: 10.1016/j.bmcl.2008.07.023. Epub 2008 Jul 10.
6
A peptoid antagonist of VEGF receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site.
Bioorg Med Chem. 2008 Jun 15;16(12):6338-43. doi: 10.1016/j.bmc.2008.05.015. Epub 2008 May 9.
7
Design of (Gd-DO3A)n-polydiamidopropanoyl-peptide nucleic acid-D(Cys-Ser-Lys-Cys) magnetic resonance contrast agents.
Biopolymers. 2008 Dec;89(12):1061-76. doi: 10.1002/bip.21059.
8
First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity.
Contrast Media Mol Imaging. 2006 Jan-Feb;1(1):30-9. doi: 10.1002/cmmi.92.
9
GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.
BMC Cancer. 2010 Jul 30;10:397. doi: 10.1186/1471-2407-10-397.
10
Dual-modality Imaging of Angiogenesis in Unstable Atherosclerotic Plaques with VEGFR2-Targeted Upconversion Nanoprobes in vivo.
Mol Imaging Biol. 2022 Oct;24(5):721-731. doi: 10.1007/s11307-022-01721-5. Epub 2022 May 23.
引用本文的文献
1
Peptoids: Smart and Emerging Candidates for the Diagnosis of Cancer, Neurological and Autoimmune Disorders.
Int J Mol Sci. 2023 Nov 15;24(22):16333. doi: 10.3390/ijms242216333.
2
A peptoid interleukin-15 receptor antagonist suppresses inflammation and arthritis in mice.
Clin Transl Immunology. 2022 Nov 24;11(11):e1432. doi: 10.1002/cti2.1432. eCollection 2022.
3
Unbiased peptoid cell screen identifies a peptoid targeting newly appeared cell surface vimentin on tumor transformed early lung cancer cells.
Bioorg Med Chem. 2022 Mar 15;58:116673. doi: 10.1016/j.bmc.2022.116673. Epub 2022 Feb 15.
4
A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells.
Bioorg Chem. 2021 Nov;116:105340. doi: 10.1016/j.bioorg.2021.105340. Epub 2021 Sep 8.
5
"Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
Int J Mol Sci. 2021 Aug 20;22(16):8963. doi: 10.3390/ijms22168963.
6
Multimodal Genetic Approach for Molecular Imaging of Vasculature in a Mouse Model of Melanoma.
Mol Imaging Biol. 2017 Apr;19(2):203-214. doi: 10.1007/s11307-016-1006-1.
7
Development of a large peptoid-DOTA combinatorial library.
Biopolymers. 2016 Sep;106(5):673-84. doi: 10.1002/bip.22883.
8
Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1.
Oncotarget. 2016 May 24;7(21):30678-90. doi: 10.18632/oncotarget.8929.
9
GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.
Sci Rep. 2015 Nov 18;5:16214. doi: 10.1038/srep16214.
10
Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells.
ACS Chem Biol. 2015 Dec 18;10(12):2891-9. doi: 10.1021/acschembio.5b00592. Epub 2015 Oct 28.
本文引用的文献
1
Large relaxivity enhancement of paramagnetic lipid nanoparticles by restricting the local motions of the Gd(III) chelates.
J Am Chem Soc. 2010 Jun 16;132(23):7836-7. doi: 10.1021/ja101518v.
2
Peptide-based probes for targeted molecular imaging.
Biochemistry. 2010 Feb 23;49(7):1364-76. doi: 10.1021/bi901135x.
3
Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.
Chem Rev. 2010 May 12;110(5):2921-59. doi: 10.1021/cr900232t.
4
Gd-functionalised Au nanoparticles as targeted contrast agents in MRI: relaxivity enhancement by polyelectrolyte coating.
Chem Commun (Camb). 2010 Jan 21;46(3):451-3. doi: 10.1039/b915223g. Epub 2009 Dec 2.
5
Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent.
Angew Chem Int Ed Engl. 2010;49(2):346-50. doi: 10.1002/anie.200905133.
6
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.
7
Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents.
Contrast Media Mol Imaging. 2009 Mar-Apr;4(2):89-100. doi: 10.1002/cmmi.267.
8
Noninvasive monitoring of HPMA copolymer-RGDfK conjugates by magnetic resonance imaging.
Pharm Res. 2009 May;26(5):1121-9. doi: 10.1007/s11095-009-9830-5. Epub 2009 Jan 22.
9
A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI.
Bioconjug Chem. 2008 Dec;19(12):2300-3. doi: 10.1021/bc800211r.
10
Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement.
Int J Nanomedicine. 2008;3(2):201-10.
Zotero 插件